∙ Parts A and B:

• Male and female subjects in good health aged 18-55 years of age at Screening.

• Body mass index (BMI) ≥30 kg/m2.

• Subjects who are medically healthy with normal or clinically insignificant screening results.

• Subjects must use a highly effective form of contraception and follow the study contraception requirements.

• Ability to communicate well with the Investigator, understand and comply with the requirements of the trial, and understand English and sign the written informed consent.

∙ Part C:

• Male and female patients with HO, aged 12-65 years of age at Screening.

• Patient has documented evidence of acquired HO defined as:

‣ Diagnosis of craniopharyngioma or other brain lesion affecting the hypothalamic region and has undergone surgery, or chemotherapy, or radiation therapy involving the hypothalamus at least 6 months before Screening, OR

⁃ Documented injury to the hypothalamus at least 6 months before Screening for which surgery/radiation is not indicated.

• Weight gain associated with the hypothalamic injury either before or following therapy (surgery and/or following chemotherapy or radiotherapy), and a BMI of ≥30 kg/m2 for patients ≥18 years of age or BMI ≥95th percentile for age and sex for patients 12 to \<18 years of age.

• Patients must use a highly effective form of contraception and follow the study contraception requirements.

• Ability to communicate with the Investigator, understand and comply with the requirements of the trial, and understand and sign the written informed consent and assent (for patients aged \<18 years), and informed consent for a parent or guardian of any patient \<18.